Abstract:There is a pressing and continued need for improved predictive power in preclinical pharmaceutical toxicology assessment as substantial numbers of drugs are still removed from the market, or from late-stage development, because of unanticipated issues of toxicity. In recent years a number of consortia have been formed with a view to integrating -omics molecular profiling strategies to increase the sensitivity and predictive power of preclinical toxicology evaluation. In this study we report on the LC-MS based proteomic analysis of the effects of the hepatotoxic compound EMD 335823 on liver from rats using an integrated discovery to targeted proteomics approach. This compound was one of a larger panel studied by a variety of molecular profiling techniques as part of the InnoMed PredTox Consortium. Label-free LC-MS analysis of hepatotoxicant EMD 335823 treated animals revealed only moderate correlation of individual protein expression with changes in mRNA expression observed by transcriptomic analysis of the same liver samples. Significantly however, analysis of the protein and transcript changes at the pathway level revealed they were in good agreement. This higher level analysis was also consistent with the previously suspected PPARα activity of the compound. Subsequently, a panel of potential biomarkers of liver toxicity was assembled from the label-free LC-MS proteomics discovery data, the previously acquired transcriptomics data and selected candidates identified from the literature. We developed and then deployed optimized selected reaction monitoring assays to undertake multiplexed measurement of 48 putative toxicity biomarkers in liver tissue. The development of the selected reaction monitoring assays was facilitated by the construction of a peptide MS/MS spectral library from pooled control and treated rat liver lysate using peptide fractionation by strong cation exchange and off-gel electrophoresis coupled to LC-MS/MS. After iterative optimization and quality control of the selected reaction monitoring assay panel, quantitative measurements of 48 putative biomarkers in the liver of EMD 335823 treated rats were carried out and this revealed that the panel is highly enriched for proteins modulated significantly on drug treatment/hepatotoxic insult. This proof-of-principle study provides a roadmap for future large scale pre-clinical toxicology biomarker verification studies whereby putative toxicity biomarkers assembled from multiple disparate sources can be evaluated at medium-high throughput by targeted MS.

Label-Free Screening of Drug-Induced Liver Injury Using Stimulated Raman Scattering Microscopy and Spectral Phasor Analysis

Causal Evaluation of Post-Marketing Drugs for Drug-induced Liver Injury from Electronic Health Records*

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

Amplification-free electrochemical biosensor detection of circulating microRNA to identify drug-induced liver injury

The liver toxicity biomarker study: phase I design and preliminary results.

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Development of novel tools for the in vitro investigation of drug-induced liver injury

Activatable Optical Probes for Fluorescence and Photoacoustic Imaging of Drug‐Induced Liver Injury

Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach

Sensitive detection of human drug-induced liver injury by measurement of microRNA-122 using single molecule arrays

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

NIR-excited imaging of drug-induced liver injury using a superoxide-activated ratiometric upconversion luminescence nanoprobe

Label-Free Imaging Techniques to Evaluate Metabolic Changes Caused by Toxic Liver Injury in PCLS

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

MicroRNAs in Drug-induced Liver Injury.

Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury

Quasi-LD-Targeted and ONOO--Responsive Fluorescent Probe for Investigating the Interaction of Nonalcoholic Fatty Liver with Drug- Induced Liver Injury

Early detection of liver injuries by the Serum enhanced binding test sensitive to albumin post-transcriptional modifications